|

A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors

RECRUITINGSponsored by Maastricht Radiation Oncology
Actively Recruiting
SponsorMaastricht Radiation Oncology
Started2022-05-01
Est. completion2028-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04865315

Summary

There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available. To achieve this goal, a broader understanding is needed of the causes of inter-and intratumoral heterogeneity; glioma dedifferentiation and invasion; the major determinants of malignancy and treatment failure in glioma patients. Patient-derived organoid (PDOs) of high-grade gliomas and low-grade gliomas will be used to identify the mechanisms that underlie this malignant behaviour and treatment resistance. This insight may be used to develop patient avatars to simultaneously test multiple new treatment modalities that are predictive for survival and quality of life of glioma patients.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* MRI diagnosis of low grade glioma (LGG) or high grade glioma (HGG)
* Age 18 years or older
* Patient is eligible for a resection of the tumor

Exclusion Criteria:

* Contra-inidication for neurosurgical resection of the tumor.
* Incapacitated patient, unable to give informed consent.

Conditions3

CancerHigh Grade GliomaLow-grade Glioma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.